In:
Pain Management, Future Medicine Ltd, Vol. 12, No. 3 ( 2022-04), p. 337-346
Abstract:
Lay abstract Ketamine is a pharmacological agent that was developed in the 1960s. There has been an increase in interest in the use of ketamine at low doses in the treatment of chronic pain syndromes. In this study, we report the results of a study that investigated patients diagnosed with a chronic noncancer pain syndrome that received a 2-week continuous ketamine infusion. We hypothesized that patients receiving IV ketamine infusion will experience acute and chronic lowering of pain intensity on the numerical rating pain level scale and reduce patient's opioid requirements. We concluded that a 10–14 day of subanesthetic ketamine infusion in chronic patients results in clinically significant lowering of patients' numerical pain score during the ketamine infusion.
Type of Medium:
Online Resource
ISSN:
1758-1869
,
1758-1877
DOI:
10.2217/pmt-2021-0064
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2022
Permalink